Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q3 2024 Earnings Presentation
11 slides from Quanterix's earnings presentation, Nov 12, 2024
Slide 1: Third Quarter 2024 Earnings
„ Third Quarter 2024 Earnings November 12, 2024
Slide 2: Forward-Looking Statements, Non-GAAP Financial Measures & Restatement
Forward-Looking Statements, Non-GAAP Financial Measures & Restatement All financial information contained in this presentation is preliminary, unaudited, based on currently available information and subject to adjustment. The supplemental schedules included in this presentation provide additional in
Slide 3: Q3 2024 Preliminary Results vs Preliminary PYQ3
Q3 2024 Preliminary Results vs Preliminary PYQ3 (in millions) Q3 GAAP Q3 Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2023 2024 2023 2024 Revenue Mix 7% 48% 30% 15% Revenue 31.6 35.7 31.6 35.7 Gross Margin $ 18.9 21.1 16.3 19.1 Gross Margin % 59.9% 58.9% 51.8% 53.4% Revenue Q3 2023 Q3 2024 8%
Slide 4: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others PUBLICATIONS BIOMARKERS INSTRUMENTS Cumulative Cumulative Placements # of units placed Cumulative $M 225 Number of Drug 3,134 559 563 1,017 Trial Projects 205 538 972 29.4 2,781 27.8 168 480 876 149 132
Slide 5: Expanding SIMOA sensitivity beyond neurology
Expanding SIMOA sensitivity beyond neurology Three New Cytokine 4-Plex Panels address translational research needs in inflammation and immunology Mood Disorder • Ultra-sensitivity Immuno-oncology • Precision Asthma • Automation Inflammation Infectious Disease related disorders IL-1𝐵𝐵 IL-6 C4PA…
Slide 6: LucentAD Complete: Now Available
LucentAD Complete: Now Available LucentAD Complete Algorithm <45 45-70 >70 provides clear Low likelihood of Intermediate likelihood High likelihood of 5 markers in 1 test AD score amyloid pathology of amyloid pathology amyloid pathology A better test, with an algorithm to leverage p-Tau 217, Aβ 40,
Slide 7: Biomarkers for FTD and ALS
Biomarkers for FTD1 and ALS2 Plasma EV Tau Isoform Ratio and TDP-43 Plasma EV TDP-43 levels were increased in ALS and The combination of EV Tau ratio and EV TDP-43 reliably in FTD patients who do not have high EV Tau ratios. discriminated between Tau and TDP-43 pathology in FTD. Biomarkers are urgen
Slide 8: Preliminary Restated GAAP Adjustments
Preliminary Restated GAAP Adjustments FY21 FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 FY23 Q1FY24 Q2FY24 Q3FY24 Revenue 110.6 105.5 28.5 31.0 31.3 31.5 122.4 32.1 34.4 35.7 Gross Profit $ 61.7 46.8 16.9 19.1 17.8 16.8 70.6 19.6 20.1 21.1 Gross Profit % 55.8% 44.4% 59.5% 61.7% 56.8% 53.2% 57.7% 61.2% 58.3% 58.
Slide 9: Preliminary Restated Non-GAAP Adjustments
Preliminary Restated Non-GAAP Adjustments FY21 FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 FY23 Q1FY24 Q2FY24 Q3FY24 Revenue 110.6 105.5 28.5 31.0 31.3 31.5 122.4 32.1 34.4 35.7 Gross Profit $ 54.8 39.6 15.1 17.5 15.2 14.7 62.5 17.5 18.0 19.1 Gross Profit % 49.6% 37.5% 53.1% 56.4% 48.6% 46.5% 51.1% 54.5% 52.3%
Slide 10: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures FY21 FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 FY23 Q1FY24 Q2FY24 Q3FY24 Preliminary Restated GAAP gross profit 63.3 47.2 16.0 19.5 18.9 18.3 72.7 18.8 21.6 21.1 Shipping and handling costs (7.9) (7.9) (1.8) (1.6) (2.6) (2.1) (8.1) (2.1) (2.1) (2.0) Preli
Slide 11: Bee
ia) Bee co) oad c i) =) o